TLSI

TriSalus Life Sciences

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/21/26

Business Summary

TriSalus Life Sciences operates in the Medical Devices space, developing specialized technologies intended for targeted therapeutic delivery. Its model likely centers on proprietary device platforms that enable physicians to administer treatments more precisely, creating value through improved clinical outcomes. Revenue generation depends on device adoption within hospital systems and procedural utilization, which can scale if embedded into treatment protocols. The moat, if it materializes, would come from intellectual property, regulatory approvals, and clinician integration that make switching costly once embedded in care pathways.

 


VALUATION

P/E

-

Market Cap ($M USD)

$259

Forward P/E

-

PEG

-

PRICE TO SALES

3.5

PRICE TO BOOK

-

EV / EBITDA

-8.3

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.84

Next Year EPS Growth Estimate

-$0.25

Next Year Revenue Growth Estimate

35.60%

Return on Equity (ROE)

205.80%

FREE CASH FLOW

Operating Margin

-59.70%

Debt-to-Equity

-

Piotroski F-Score

4

Altman Z-Score

-11.4

Return on Invested Capital (ROIC)

-11059.70%

Current Ratio

2.8

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Gainseekers Quantitative Analysis

Summary

The financial profile here is distressed and speculative. With no P/E or Forward P/E available, deeply negative EPS of -8.3, and an Altman Z-Score of -11.4, this company screens as financially fragile with elevated bankruptcy risk. The market cap of $259M against a Price/Sales of 3.5 suggests investors are paying a growth multiple despite the absence of profitability and a catastrophic ROIC of -11059.70%. This is not a misunderstood compounder—it is a high-risk turnaround story where survival, not growth, is the central question.

AI Exposure / Tech Reliance

Operating in Medical Devices within Healthcare, the company sits in a sector that increasingly integrates AI into diagnostics, imaging, and procedural optimization. Medical technology firms that successfully layer AI-driven data insights onto device platforms can create switching costs and recurring revenue streams. However, without profitability or evidence of operating leverage, the ability to internally fund meaningful AI integration may be constrained.

The Bull Case

A speculative value investor could argue that extreme negativity is already priced in. The $259M market cap paired with 35.60% Return on Equity and a 205.80% Operating Margin suggests that, at least on paper, there are operational dynamics that could swing dramatically if stabilized. A Piotroski F-Score of 4 indicates middling but not catastrophic fundamental health, while a solid Current Ratio of 2.8 shows short-term liquidity is not immediately strained. If management can convert liquidity into sustainable earnings and narrow losses toward the -$1.84 EPS expected next year, the operating structure could create sharp upside from depressed levels.

The Bear Case

The bear case is overwhelming. EPS of -8.3, projected EPS still negative at -$1.84 next year, and Sales Growth Next Year of -$0.25 signal contraction rather than scaling. Debt/Equity of -59.70% and a catastrophic ROIC of -11059.70% point to severe capital destruction, while the Altman Z-Score of -11.4 places the firm deep in financial distress territory. Paying 3.5x sales for a company with negative earnings, no dividend support, no P/E anchor, and extreme volatility in returns is structurally dangerous—this is balance-sheet risk masquerading as growth optionality.

Market Sentiment & Smart Money

Short Interest %

2.30%

Analyst Consensus

1.33

Average Analyst Price Target

$9.20

Institutional Ownership %

19.10%

1-Year Beta

1.11

Insider Buying % (6 Mo)

28.20%%

Distance to 52-Week High

53.10%

Distance to 52-Week Low

123.40%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.